Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 90.49%

Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR is 90.49% for the Trailing 12 Months (TTM) ending March 31, 2024, a -84.80% change year over year. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 21.51 M, a 29.08% change year over year.
Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 16.66 M, a 356.37% change year over year.
Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 3.65 M, a 5,604.69% change year over year.
Biomea Fusion Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 64.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends